Equities analysts predict that Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) will post earnings of ($0.67) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aerie Pharmaceuticals’ earnings. The highest EPS estimate is ($0.62) and the lowest is ($0.72). Aerie Pharmaceuticals posted earnings per share of ($0.72) during the same quarter last year, which suggests a positive year over year growth rate of 6.9%. The business is scheduled to report its next earnings report on Tuesday, March 6th.
On average, analysts expect that Aerie Pharmaceuticals will report full year earnings of ($2.54) per share for the current year, with EPS estimates ranging from ($2.60) to ($2.48). For the next year, analysts expect that the business will report earnings of ($2.08) per share, with EPS estimates ranging from ($2.39) to ($1.77). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Aerie Pharmaceuticals.
Several research firms recently weighed in on AERI. Mizuho reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Friday, November 3rd. Guggenheim began coverage on shares of Aerie Pharmaceuticals in a research note on Monday, October 23rd. They set a “buy” rating and a $80.00 target price for the company. Zacks Investment Research raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Needham & Company LLC reaffirmed a “buy” rating and set a $76.00 target price (up from $65.00) on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. Finally, Canaccord Genuity reaffirmed a “positive” rating and set a $73.00 target price (up from $65.00) on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the stock. Aerie Pharmaceuticals presently has an average rating of “Buy” and an average target price of $70.93.
Institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. lifted its holdings in shares of Aerie Pharmaceuticals by 11.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after acquiring an additional 275 shares during the last quarter. Quantbot Technologies LP lifted its holdings in shares of Aerie Pharmaceuticals by 792.5% in the 3rd quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock worth $144,000 after acquiring an additional 2,647 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Aerie Pharmaceuticals by 2,711.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after acquiring an additional 3,579 shares during the last quarter. Amalgamated Bank bought a new stake in shares of Aerie Pharmaceuticals in the 2nd quarter worth about $204,000. Finally, Palisade Capital Management LLC NJ bought a new stake in shares of Aerie Pharmaceuticals in the 2nd quarter worth about $212,000. Hedge funds and other institutional investors own 95.71% of the company’s stock.
Aerie Pharmaceuticals (NASDAQ AERI) opened at $60.60 on Wednesday. Aerie Pharmaceuticals has a 52 week low of $35.20 and a 52 week high of $66.25. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.